Earnings ·
Innoviva reports Q3 revenue of $106.1M and a net loss of $73.9M
INVAInnoviva, Inc.
Innoviva reported third-quarter 2026 total revenue of $106.1 million, a 1.6% decrease from the prior year period. U.S. net product sales grew 45% to $43.3 million, driven by GIAPREZA and XACDURO, while royalty revenue remained stable at $58.1 million. The company reported a net loss of $73.9 million, or $1.03 per share, primarily due to a $139.5 million decline in the fair value of equity investments, notably Armata Pharmaceuticals. Operating income increased 21.9% to $42.2 million. Innoviva repurchased 1.2 million shares for $26.3 million under its buyback program. Innoviva is a diversified biopharmaceutical company with a core royalties portfolio and a leading critical care and infectious disease platform.